News | Business
26 Jun 2017 14:02
NZCity News
NZCity CalculatorReturn to NZCity

  • Start Page
  • Personalise
  • News
  • Sport
  • Weather
  • Olympic Games
  • Ski Report
  • Shopping
  • Jobs
  • Horoscopes
  • Lotto Results
  • Photo Gallery
  • Site Gallery
  • TVNow
  • Dating
  • SearchNZ
  • NZSearch
  • Crime.co.nz
  • RugbyLeague
  • Make Home
  • About NZCity
  • Contact NZCity
  • Your Privacy
  • Advertising
  • Login
  • Join for Free

  •   Home > News > Business

    Pacific Edge gets $3m extension to grant

    Pacific Edge has won a two-year extension to its research grant to fund the development of its Cxbladder products for bladder cancer detection.

    21 March 2017

    Pacific Edge has won a two-year extension to its Callaghan Innovation research grant to fund the development of its Cxbladder diagnostic suite of products for bladder cancer detection.

    The Dunedin-based firm has received up to $3 million of extra funding for research and development spread over two years, on top of an initial three-year grant of $4.5m it received in 2014, it said in a statement.

    Since the first grant was awarded, Pacific Edge has launched three new products to add to the original bladder cancer diagnostics test, with each test addressing different clinical needs.

    The shares rose 3.5 per cent to 59 cents.

    "Investment into research and development is a major focus for Pacific Edge and we are continually looking at how we can provide better and more targeted diagnostic tools for clinicians and their patients," chief executive David Darling said.

    "The Growth Grant supplements Pacific Edge's own investment into R&D and will enable us to bring new innovations through into new products and product improvements."

    The company raised $8 million in February through a share placement to institutional investors to shore up its balance sheet as it ramps up efforts to lift commercial growth.

    It started making commercial sales in 2013 and at the time was targeting $100m in gross revenue within five years.

    The recent capital raise left it with $9m of cash to fund its immediate growth needs, and when reporting its first half result in November it signalled plans to have all four Cxbladder products fully launched in the US by 2018.

    # (BusinessDesk receives funding from Callaghan Innovation to help cover the commercialisation of innovation.)


    NZN




    © 2017 NZN, NZCity


     Other Business News
     26 Jun: NZ King Salmon lifts earnings guidance
     26 Jun: NZD edges up amid bets on stronger kiwi
     26 Jun: Tower in trading halt as Vero lifts offer
     25 Jun: Moeraki Boulders gets speed control
     25 Jun: Posties' union delivers NZ Post broadside
     25 Jun: Kiwifruit class action headed to court
     25 Jun: Call to track building materials
     Top Stories

    RUGBY RUGBY
    All Blacks show Hurricanes the way More...


    BUSINESS BUSINESS
    NZ King Salmon lifts earnings guidance More...



     Today's News

    Politics:
    Donald Trump, Narendra Modi parallels excited conservative Hindu nationalist group 13:57

    Golf:
    Ko slips further down world rankings 13:47

    Accident and Emergency:
    Otago plane crash investigation to begin 13:27

    International:
    Bali bombing: Guantanamo Bay detainee charged over 2002 attack, Julie Bishop welcomes move 13:17

    Boxing:
    Parker to fight Fury in Manchester 13:07

    Sailing:
    Dawson bronze wraps up World Cup regatta 12:27

    International:
    The silent partner: What it was like for journalist Eliza Harvey when her correspondent husband was shot 11:57

    Law and Order:
    Sir Ngatata Love's appeal dismissed 11:57

    Business:
    NZ King Salmon lifts earnings guidance 11:07

    Sailing:
    Team NZ must keep improving: Burling 10:48


     News Search






    Power Search


    © 2017 New Zealand City Ltd